Wegovy was approved by the U.S. health regulator last month for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes. The additional approval would expand Medicare coverage for Wegovy and coverage by other insurers for such adults with heart conditions.
The approval for Velsipity follows backing from the European Medicines Agency's panel of experts in December. The drug was approved for use in patients aged 16 or older and who did not show adequate response or were intolerant to previous treatment, Pfizer said. The approval, applicable in all 27 countries of the European Union, is based on studies from two late-stage trials that showed the drug was effective and safe in eligible patients.
Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discusses the importance of lung cancer screening in eligible patients, including the need for primary care providers to ensure screening is being implemented.
The life-saving COVID-19 drug few are using beckershospitalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from beckershospitalreview.com Daily Mail and Mail on Sunday newspapers.